nodes	percent_of_prediction	percent_of_DWPC	metapath
Abiraterone—Testosterone—Hydrocortisone—psoriasis	0.167	0.543	CrCrCtD
Abiraterone—Testosterone—Prednisolone—psoriasis	0.14	0.457	CrCrCtD
Abiraterone—CYP17A1—Dexamethasone—psoriasis	0.0797	0.15	CbGbCtD
Abiraterone—ALB—Acitretin—psoriasis	0.0537	0.101	CbGbCtD
Abiraterone—CYP2C8—Tazarotene—psoriasis	0.0525	0.0987	CbGbCtD
Abiraterone—ABCC1—Cyclosporine—psoriasis	0.0413	0.0777	CbGbCtD
Abiraterone—ALB—Mycophenolate mofetil—psoriasis	0.0251	0.0473	CbGbCtD
Abiraterone—CYP2D6—Hydroxyurea—psoriasis	0.0236	0.0444	CbGbCtD
Abiraterone—CYP2C8—Cholecalciferol—psoriasis	0.0224	0.0421	CbGbCtD
Abiraterone—ABCC1—Methotrexate—psoriasis	0.0219	0.0411	CbGbCtD
Abiraterone—ALB—Prednisone—psoriasis	0.0201	0.0378	CbGbCtD
Abiraterone—CYP2C8—Mycophenolate mofetil—psoriasis	0.0194	0.0365	CbGbCtD
Abiraterone—CYP3A4—Calcitriol—psoriasis	0.0176	0.0332	CbGbCtD
Abiraterone—CYP2C8—Hydrocortisone—psoriasis	0.0156	0.0293	CbGbCtD
Abiraterone—CYP2C8—Cyclosporine—psoriasis	0.0147	0.0277	CbGbCtD
Abiraterone—CYP2D6—Cholecalciferol—psoriasis	0.0143	0.0269	CbGbCtD
Abiraterone—CYP3A4—Methoxsalen—psoriasis	0.0137	0.0258	CbGbCtD
Abiraterone—ALB—Methotrexate—psoriasis	0.0101	0.019	CbGbCtD
Abiraterone—CYP2C8—Dexamethasone—psoriasis	0.0097	0.0182	CbGbCtD
Abiraterone—CYP2D6—Cyclosporine—psoriasis	0.00939	0.0177	CbGbCtD
Abiraterone—CYP3A4—Cholecalciferol—psoriasis	0.00909	0.0171	CbGbCtD
Abiraterone—CYP3A4—Mycophenolate mofetil—psoriasis	0.00788	0.0148	CbGbCtD
Abiraterone—CYP3A4—Triamcinolone—psoriasis	0.00788	0.0148	CbGbCtD
Abiraterone—CYP3A4—Betamethasone—psoriasis	0.00676	0.0127	CbGbCtD
Abiraterone—CYP3A4—Prednisolone—psoriasis	0.00667	0.0125	CbGbCtD
Abiraterone—CYP3A4—Hydrocortisone—psoriasis	0.00632	0.0119	CbGbCtD
Abiraterone—CYP3A4—Prednisone—psoriasis	0.0063	0.0118	CbGbCtD
Abiraterone—CYP2D6—Dexamethasone—psoriasis	0.00618	0.0116	CbGbCtD
Abiraterone—CYP3A4—Cyclosporine—psoriasis	0.00597	0.0112	CbGbCtD
Abiraterone—CYP3A4—Dexamethasone—psoriasis	0.00393	0.0074	CbGbCtD
Abiraterone—SULT2A1—Corticotropin-releasing hormone—IVL—psoriasis	0.00155	0.0656	CbGpPWpGaD
Abiraterone—SULT2A1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.00149	0.0628	CbGpPWpGaD
Abiraterone—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.00126	0.0534	CbGpPWpGaD
Abiraterone—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00104	0.0438	CbGpPWpGaD
Abiraterone—CYP17A1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000986	0.0417	CbGpPWpGaD
Abiraterone—CYP17A1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000973	0.0411	CbGpPWpGaD
Abiraterone—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000966	0.0409	CbGpPWpGaD
Abiraterone—SULT2A1—Biological oxidations—CYP2S1—psoriasis	0.0008	0.0338	CbGpPWpGaD
Abiraterone—CYP17A1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000799	0.0338	CbGpPWpGaD
Abiraterone—SULT2A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000789	0.0334	CbGpPWpGaD
Abiraterone—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.000782	0.0331	CbGpPWpGaD
Abiraterone—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000642	0.0272	CbGpPWpGaD
Abiraterone—SULT2A1—PPARA activates gene expression—CARM1—psoriasis	0.000558	0.0236	CbGpPWpGaD
Abiraterone—SULT2A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000547	0.0231	CbGpPWpGaD
Abiraterone—CYP17A1—Biological oxidations—CYP2S1—psoriasis	0.000424	0.018	CbGpPWpGaD
Abiraterone—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.00042	0.0178	CbGpPWpGaD
Abiraterone—CYP17A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000419	0.0177	CbGpPWpGaD
Abiraterone—SULT2A1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000377	0.0159	CbGpPWpGaD
Abiraterone—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000325	0.0137	CbGpPWpGaD
Abiraterone—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00032	0.0136	CbGpPWpGaD
Abiraterone—SULT2A1—Corticotropin-releasing hormone—NFKBIA—psoriasis	0.000287	0.0121	CbGpPWpGaD
Abiraterone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000267	0.0113	CbGpPWpGaD
Abiraterone—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000263	0.0111	CbGpPWpGaD
Abiraterone—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000263	0.0111	CbGpPWpGaD
Abiraterone—SULT2A1—PPARA activates gene expression—PPARG—psoriasis	0.000232	0.00984	CbGpPWpGaD
Abiraterone—ALB—HDL-mediated lipid transport—APOE—psoriasis	0.000228	0.00966	CbGpPWpGaD
Abiraterone—SULT2A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	0.000228	0.00963	CbGpPWpGaD
Abiraterone—Urinary tract disorder—Mycophenolate mofetil—psoriasis	0.000222	0.00162	CcSEcCtD
Abiraterone—Connective tissue disorder—Mycophenolate mofetil—psoriasis	0.000221	0.00161	CcSEcCtD
Abiraterone—Asthenia—Acitretin—psoriasis	0.000221	0.00161	CcSEcCtD
Abiraterone—Urethral disorder—Mycophenolate mofetil—psoriasis	0.000221	0.00161	CcSEcCtD
Abiraterone—Vomiting—Calcitriol—psoriasis	0.00022	0.00161	CcSEcCtD
Abiraterone—Rash—Calcitriol—psoriasis	0.000218	0.00159	CcSEcCtD
Abiraterone—Dermatitis—Calcitriol—psoriasis	0.000218	0.00159	CcSEcCtD
Abiraterone—Cough—Mycophenolic acid—psoriasis	0.000217	0.00158	CcSEcCtD
Abiraterone—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000216	0.00914	CbGpPWpGaD
Abiraterone—Dyspnoea—Hydroxyurea—psoriasis	0.000216	0.00157	CcSEcCtD
Abiraterone—Hypertension—Mycophenolic acid—psoriasis	0.000214	0.00156	CcSEcCtD
Abiraterone—Dyspepsia—Hydroxyurea—psoriasis	0.000213	0.00155	CcSEcCtD
Abiraterone—Acute coronary syndrome—Triamcinolone—psoriasis	0.000212	0.00155	CcSEcCtD
Abiraterone—Myalgia—Mycophenolic acid—psoriasis	0.000211	0.00154	CcSEcCtD
Abiraterone—Chest pain—Mycophenolic acid—psoriasis	0.000211	0.00154	CcSEcCtD
Abiraterone—Diarrhoea—Acitretin—psoriasis	0.000211	0.00154	CcSEcCtD
Abiraterone—Myocardial infarction—Triamcinolone—psoriasis	0.000211	0.00154	CcSEcCtD
Abiraterone—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.00021	0.00153	CcSEcCtD
Abiraterone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.00021	0.00153	CcSEcCtD
Abiraterone—Angiopathy—Cyclosporine—psoriasis	0.000209	0.00153	CcSEcCtD
Abiraterone—Cardiac disorder—Mycophenolate mofetil—psoriasis	0.000209	0.00152	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.000209	0.00152	CcSEcCtD
Abiraterone—Discomfort—Mycophenolic acid—psoriasis	0.000209	0.00152	CcSEcCtD
Abiraterone—Fatigue—Hydroxyurea—psoriasis	0.000209	0.00152	CcSEcCtD
Abiraterone—Mediastinal disorder—Cyclosporine—psoriasis	0.000208	0.00152	CcSEcCtD
Abiraterone—Constipation—Hydroxyurea—psoriasis	0.000207	0.00151	CcSEcCtD
Abiraterone—Arrhythmia—Cyclosporine—psoriasis	0.000206	0.0015	CcSEcCtD
Abiraterone—SULT2A1—Corticotropin-releasing hormone—CXCL8—psoriasis	0.000205	0.00866	CbGpPWpGaD
Abiraterone—Angiopathy—Mycophenolate mofetil—psoriasis	0.000204	0.00149	CcSEcCtD
Abiraterone—Mediastinal disorder—Mycophenolate mofetil—psoriasis	0.000203	0.00148	CcSEcCtD
Abiraterone—Oedema—Mycophenolic acid—psoriasis	0.000203	0.00148	CcSEcCtD
Abiraterone—Mental disorder—Cyclosporine—psoriasis	0.000202	0.00147	CcSEcCtD
Abiraterone—Connective tissue disorder—Hydrocortisone—psoriasis	0.000202	0.00147	CcSEcCtD
Abiraterone—Infection—Mycophenolic acid—psoriasis	0.000201	0.00147	CcSEcCtD
Abiraterone—Arrhythmia—Mycophenolate mofetil—psoriasis	0.000201	0.00147	CcSEcCtD
Abiraterone—Hypokalaemia—Prednisone—psoriasis	0.000201	0.00146	CcSEcCtD
Abiraterone—Hyperglycaemia—Dexamethasone—psoriasis	0.000197	0.00144	CcSEcCtD
Abiraterone—Hyperglycaemia—Betamethasone—psoriasis	0.000197	0.00144	CcSEcCtD
Abiraterone—Mental disorder—Mycophenolate mofetil—psoriasis	0.000197	0.00144	CcSEcCtD
Abiraterone—Skin disorder—Mycophenolic acid—psoriasis	0.000197	0.00144	CcSEcCtD
Abiraterone—Vomiting—Acitretin—psoriasis	0.000196	0.00143	CcSEcCtD
Abiraterone—Vomiting—Fluocinolone Acetonide—psoriasis	0.000195	0.00143	CcSEcCtD
Abiraterone—Alanine aminotransferase increased—Prednisone—psoriasis	0.000195	0.00142	CcSEcCtD
Abiraterone—Rash—Acitretin—psoriasis	0.000194	0.00142	CcSEcCtD
Abiraterone—Dermatitis—Acitretin—psoriasis	0.000194	0.00142	CcSEcCtD
Abiraterone—Rash—Fluocinolone Acetonide—psoriasis	0.000194	0.00141	CcSEcCtD
Abiraterone—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000194	0.00141	CcSEcCtD
Abiraterone—Acute coronary syndrome—Betamethasone—psoriasis	0.000192	0.0014	CcSEcCtD
Abiraterone—Acute coronary syndrome—Dexamethasone—psoriasis	0.000192	0.0014	CcSEcCtD
Abiraterone—Myocardial infarction—Dexamethasone—psoriasis	0.000191	0.0014	CcSEcCtD
Abiraterone—Myocardial infarction—Betamethasone—psoriasis	0.000191	0.0014	CcSEcCtD
Abiraterone—Body temperature increased—Hydroxyurea—psoriasis	0.000191	0.0014	CcSEcCtD
Abiraterone—ABCC1—S1P1 pathway—VEGFA—psoriasis	0.000188	0.00795	CbGpPWpGaD
Abiraterone—Arrhythmia—Prednisolone—psoriasis	0.000188	0.00137	CcSEcCtD
Abiraterone—Anaemia—Cyclosporine—psoriasis	0.000186	0.00135	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	0.000185	0.00135	CcSEcCtD
Abiraterone—Insomnia—Mycophenolic acid—psoriasis	0.000183	0.00134	CcSEcCtD
Abiraterone—Arrhythmia—Hydrocortisone—psoriasis	0.000183	0.00134	CcSEcCtD
Abiraterone—SULT2A1—Corticotropin-releasing hormone—NFKB1—psoriasis	0.000183	0.00775	CbGpPWpGaD
Abiraterone—Anaemia—Mycophenolate mofetil—psoriasis	0.000181	0.00132	CcSEcCtD
Abiraterone—Dyspnoea—Mycophenolic acid—psoriasis	0.000181	0.00132	CcSEcCtD
Abiraterone—Mental disorder—Hydrocortisone—psoriasis	0.00018	0.00131	CcSEcCtD
Abiraterone—Dyspepsia—Mycophenolic acid—psoriasis	0.000178	0.0013	CcSEcCtD
Abiraterone—Cough—Cyclosporine—psoriasis	0.000175	0.00128	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000175	0.00128	CcSEcCtD
Abiraterone—Fatigue—Mycophenolic acid—psoriasis	0.000175	0.00127	CcSEcCtD
Abiraterone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000174	0.00737	CbGpPWpGaD
Abiraterone—Asthenia—Hydroxyurea—psoriasis	0.000174	0.00127	CcSEcCtD
Abiraterone—Hypertension—Cyclosporine—psoriasis	0.000173	0.00126	CcSEcCtD
Abiraterone—Constipation—Mycophenolic acid—psoriasis	0.000173	0.00126	CcSEcCtD
Abiraterone—Arrhythmia—Triamcinolone—psoriasis	0.000172	0.00126	CcSEcCtD
Abiraterone—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000172	0.00728	CbGpPWpGaD
Abiraterone—Hyperglycaemia—Prednisone—psoriasis	0.000172	0.00125	CcSEcCtD
Abiraterone—Myalgia—Cyclosporine—psoriasis	0.000171	0.00125	CcSEcCtD
Abiraterone—Chest pain—Cyclosporine—psoriasis	0.000171	0.00125	CcSEcCtD
Abiraterone—Cough—Mycophenolate mofetil—psoriasis	0.000171	0.00125	CcSEcCtD
Abiraterone—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.00017	0.00124	CcSEcCtD
Abiraterone—Hypertension—Mycophenolate mofetil—psoriasis	0.000169	0.00123	CcSEcCtD
Abiraterone—Discomfort—Cyclosporine—psoriasis	0.000169	0.00123	CcSEcCtD
Abiraterone—Acute coronary syndrome—Prednisone—psoriasis	0.000168	0.00122	CcSEcCtD
Abiraterone—Myalgia—Mycophenolate mofetil—psoriasis	0.000167	0.00122	CcSEcCtD
Abiraterone—Chest pain—Mycophenolate mofetil—psoriasis	0.000167	0.00122	CcSEcCtD
Abiraterone—Myocardial infarction—Prednisone—psoriasis	0.000167	0.00122	CcSEcCtD
Abiraterone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000166	0.00121	CcSEcCtD
Abiraterone—Diarrhoea—Hydroxyurea—psoriasis	0.000166	0.00121	CcSEcCtD
Abiraterone—Discomfort—Mycophenolate mofetil—psoriasis	0.000165	0.0012	CcSEcCtD
Abiraterone—Oedema—Cyclosporine—psoriasis	0.000164	0.0012	CcSEcCtD
Abiraterone—Infection—Cyclosporine—psoriasis	0.000163	0.00119	CcSEcCtD
Abiraterone—SULT2A1—Metabolism—NDUFA5—psoriasis	0.000161	0.00681	CbGpPWpGaD
Abiraterone—Body temperature increased—Mycophenolic acid—psoriasis	0.00016	0.00117	CcSEcCtD
Abiraterone—Oedema—Mycophenolate mofetil—psoriasis	0.00016	0.00117	CcSEcCtD
Abiraterone—Skin disorder—Cyclosporine—psoriasis	0.000159	0.00116	CcSEcCtD
Abiraterone—Angiopathy—Betamethasone—psoriasis	0.000159	0.00116	CcSEcCtD
Abiraterone—Angiopathy—Dexamethasone—psoriasis	0.000159	0.00116	CcSEcCtD
Abiraterone—Infection—Mycophenolate mofetil—psoriasis	0.000159	0.00116	CcSEcCtD
Abiraterone—Hypertension—Prednisolone—psoriasis	0.000158	0.00115	CcSEcCtD
Abiraterone—SULT2A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	0.000157	0.00663	CbGpPWpGaD
Abiraterone—Arrhythmia—Betamethasone—psoriasis	0.000157	0.00114	CcSEcCtD
Abiraterone—Arrhythmia—Dexamethasone—psoriasis	0.000157	0.00114	CcSEcCtD
Abiraterone—Skin disorder—Mycophenolate mofetil—psoriasis	0.000155	0.00113	CcSEcCtD
Abiraterone—Hypertension—Hydrocortisone—psoriasis	0.000154	0.00112	CcSEcCtD
Abiraterone—Vomiting—Hydroxyurea—psoriasis	0.000154	0.00112	CcSEcCtD
Abiraterone—Discomfort—Prednisolone—psoriasis	0.000154	0.00112	CcSEcCtD
Abiraterone—Rash—Hydroxyurea—psoriasis	0.000153	0.00111	CcSEcCtD
Abiraterone—Dermatitis—Hydroxyurea—psoriasis	0.000152	0.00111	CcSEcCtD
Abiraterone—Myalgia—Hydrocortisone—psoriasis	0.000152	0.00111	CcSEcCtD
Abiraterone—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000151	0.0011	CcSEcCtD
Abiraterone—Discomfort—Hydrocortisone—psoriasis	0.00015	0.0011	CcSEcCtD
Abiraterone—SULT2A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.00015	0.00635	CbGpPWpGaD
Abiraterone—Connective tissue disorder—Prednisone—psoriasis	0.00015	0.00109	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000149	0.00109	CcSEcCtD
Abiraterone—Oedema—Prednisolone—psoriasis	0.000149	0.00109	CcSEcCtD
Abiraterone—Insomnia—Cyclosporine—psoriasis	0.000148	0.00108	CcSEcCtD
Abiraterone—Upper respiratory tract infection—Methotrexate—psoriasis	0.000148	0.00108	CcSEcCtD
Abiraterone—Cough—Triamcinolone—psoriasis	0.000147	0.00107	CcSEcCtD
Abiraterone—Dyspnoea—Cyclosporine—psoriasis	0.000146	0.00107	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000146	0.00106	CcSEcCtD
Abiraterone—Oedema—Hydrocortisone—psoriasis	0.000146	0.00106	CcSEcCtD
Abiraterone—Asthenia—Mycophenolic acid—psoriasis	0.000145	0.00106	CcSEcCtD
Abiraterone—Hypertension—Triamcinolone—psoriasis	0.000145	0.00106	CcSEcCtD
Abiraterone—Infection—Hydrocortisone—psoriasis	0.000145	0.00106	CcSEcCtD
Abiraterone—Insomnia—Mycophenolate mofetil—psoriasis	0.000145	0.00106	CcSEcCtD
Abiraterone—Dyspepsia—Cyclosporine—psoriasis	0.000144	0.00105	CcSEcCtD
Abiraterone—Myalgia—Triamcinolone—psoriasis	0.000143	0.00104	CcSEcCtD
Abiraterone—Pneumonia—Methotrexate—psoriasis	0.000143	0.00104	CcSEcCtD
Abiraterone—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000143	0.00104	CcSEcCtD
Abiraterone—Infestation—Methotrexate—psoriasis	0.000142	0.00104	CcSEcCtD
Abiraterone—Infestation NOS—Methotrexate—psoriasis	0.000142	0.00104	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000142	0.00103	CcSEcCtD
Abiraterone—Skin disorder—Hydrocortisone—psoriasis	0.000142	0.00103	CcSEcCtD
Abiraterone—Discomfort—Triamcinolone—psoriasis	0.000141	0.00103	CcSEcCtD
Abiraterone—Fatigue—Cyclosporine—psoriasis	0.000141	0.00103	CcSEcCtD
Abiraterone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000141	0.00598	CbGpPWpGaD
Abiraterone—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000141	0.00103	CcSEcCtD
Abiraterone—Constipation—Cyclosporine—psoriasis	0.00014	0.00102	CcSEcCtD
Abiraterone—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.00014	0.00591	CbGpPWpGaD
Abiraterone—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000139	0.0059	CbGpPWpGaD
Abiraterone—Diarrhoea—Mycophenolic acid—psoriasis	0.000139	0.00101	CcSEcCtD
Abiraterone—Angiopathy—Prednisone—psoriasis	0.000138	0.00101	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000138	0.00101	CcSEcCtD
Abiraterone—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000138	0.00583	CbGpPWpGaD
Abiraterone—Oedema—Triamcinolone—psoriasis	0.000137	0.001	CcSEcCtD
Abiraterone—SULT2A1—Metabolism—CYP2S1—psoriasis	0.000137	0.00579	CbGpPWpGaD
Abiraterone—Constipation—Mycophenolate mofetil—psoriasis	0.000137	0.000997	CcSEcCtD
Abiraterone—Arrhythmia—Prednisone—psoriasis	0.000136	0.000994	CcSEcCtD
Abiraterone—Infection—Triamcinolone—psoriasis	0.000136	0.000994	CcSEcCtD
Abiraterone—Haematuria—Methotrexate—psoriasis	0.000135	0.000988	CcSEcCtD
Abiraterone—Insomnia—Prednisolone—psoriasis	0.000135	0.000984	CcSEcCtD
Abiraterone—Mental disorder—Prednisone—psoriasis	0.000134	0.000975	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000133	0.000968	CcSEcCtD
Abiraterone—Insomnia—Hydrocortisone—psoriasis	0.000132	0.000961	CcSEcCtD
Abiraterone—Hypertension—Dexamethasone—psoriasis	0.000132	0.00096	CcSEcCtD
Abiraterone—Hypertension—Betamethasone—psoriasis	0.000132	0.00096	CcSEcCtD
Abiraterone—ALB—Lipoprotein metabolism—APOE—psoriasis	0.000131	0.00555	CbGpPWpGaD
Abiraterone—Myalgia—Dexamethasone—psoriasis	0.00013	0.000947	CcSEcCtD
Abiraterone—Myalgia—Betamethasone—psoriasis	0.00013	0.000947	CcSEcCtD
Abiraterone—Body temperature increased—Cyclosporine—psoriasis	0.00013	0.000945	CcSEcCtD
Abiraterone—Vomiting—Mycophenolic acid—psoriasis	0.000129	0.00094	CcSEcCtD
Abiraterone—Discomfort—Dexamethasone—psoriasis	0.000128	0.000936	CcSEcCtD
Abiraterone—Discomfort—Betamethasone—psoriasis	0.000128	0.000936	CcSEcCtD
Abiraterone—Dyspepsia—Hydrocortisone—psoriasis	0.000128	0.000935	CcSEcCtD
Abiraterone—Rash—Mycophenolic acid—psoriasis	0.000128	0.000932	CcSEcCtD
Abiraterone—Dermatitis—Mycophenolic acid—psoriasis	0.000128	0.000931	CcSEcCtD
Abiraterone—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000126	0.000922	CcSEcCtD
Abiraterone—Urinary tract disorder—Methotrexate—psoriasis	0.000126	0.000919	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000126	0.000917	CcSEcCtD
Abiraterone—Fatigue—Hydrocortisone—psoriasis	0.000126	0.000916	CcSEcCtD
Abiraterone—Urethral disorder—Methotrexate—psoriasis	0.000125	0.000912	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000125	0.000912	CcSEcCtD
Abiraterone—Oedema—Betamethasone—psoriasis	0.000124	0.000908	CcSEcCtD
Abiraterone—Oedema—Dexamethasone—psoriasis	0.000124	0.000908	CcSEcCtD
Abiraterone—Insomnia—Triamcinolone—psoriasis	0.000124	0.000905	CcSEcCtD
Abiraterone—Infection—Betamethasone—psoriasis	0.000124	0.000902	CcSEcCtD
Abiraterone—Infection—Dexamethasone—psoriasis	0.000124	0.000902	CcSEcCtD
Abiraterone—Anaemia—Prednisone—psoriasis	0.000123	0.000895	CcSEcCtD
Abiraterone—Dyspnoea—Triamcinolone—psoriasis	0.000122	0.000892	CcSEcCtD
Abiraterone—Dyspepsia—Triamcinolone—psoriasis	0.000121	0.000881	CcSEcCtD
Abiraterone—Cardiac disorder—Methotrexate—psoriasis	0.000118	0.000863	CcSEcCtD
Abiraterone—Fatigue—Triamcinolone—psoriasis	0.000118	0.000863	CcSEcCtD
Abiraterone—Asthenia—Cyclosporine—psoriasis	0.000118	0.000858	CcSEcCtD
Abiraterone—Angiopathy—Methotrexate—psoriasis	0.000116	0.000844	CcSEcCtD
Abiraterone—Body temperature increased—Hydrocortisone—psoriasis	0.000115	0.00084	CcSEcCtD
Abiraterone—Mediastinal disorder—Methotrexate—psoriasis	0.000115	0.000838	CcSEcCtD
Abiraterone—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000115	0.00486	CbGpPWpGaD
Abiraterone—Asthenia—Mycophenolate mofetil—psoriasis	0.000115	0.000837	CcSEcCtD
Abiraterone—Hypertension—Prednisone—psoriasis	0.000115	0.000836	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000113	0.000827	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000113	0.000827	CcSEcCtD
Abiraterone—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000113	0.00479	CbGpPWpGaD
Abiraterone—Myalgia—Prednisone—psoriasis	0.000113	0.000825	CcSEcCtD
Abiraterone—Insomnia—Betamethasone—psoriasis	0.000113	0.000821	CcSEcCtD
Abiraterone—Insomnia—Dexamethasone—psoriasis	0.000113	0.000821	CcSEcCtD
Abiraterone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000112	0.000819	CcSEcCtD
Abiraterone—Diarrhoea—Cyclosporine—psoriasis	0.000112	0.000818	CcSEcCtD
Abiraterone—Discomfort—Prednisone—psoriasis	0.000112	0.000815	CcSEcCtD
Abiraterone—Mental disorder—Methotrexate—psoriasis	0.000112	0.000815	CcSEcCtD
Abiraterone—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000111	0.00471	CbGpPWpGaD
Abiraterone—Dyspepsia—Dexamethasone—psoriasis	0.00011	0.000799	CcSEcCtD
Abiraterone—Dyspepsia—Betamethasone—psoriasis	0.00011	0.000799	CcSEcCtD
Abiraterone—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000109	0.000798	CcSEcCtD
Abiraterone—Body temperature increased—Triamcinolone—psoriasis	0.000108	0.000791	CcSEcCtD
Abiraterone—Oedema—Prednisone—psoriasis	0.000108	0.000791	CcSEcCtD
Abiraterone—Infection—Prednisone—psoriasis	0.000108	0.000786	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000107	0.000784	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Betamethasone—psoriasis	0.000107	0.000784	CcSEcCtD
Abiraterone—Fatigue—Dexamethasone—psoriasis	0.000107	0.000783	CcSEcCtD
Abiraterone—Fatigue—Betamethasone—psoriasis	0.000107	0.000783	CcSEcCtD
Abiraterone—ALB—Hemostasis—SERPINB8—psoriasis	0.000107	0.00453	CbGpPWpGaD
Abiraterone—Skin disorder—Prednisone—psoriasis	0.000105	0.000768	CcSEcCtD
Abiraterone—Asthenia—Hydrocortisone—psoriasis	0.000105	0.000762	CcSEcCtD
Abiraterone—Vomiting—Cyclosporine—psoriasis	0.000104	0.00076	CcSEcCtD
Abiraterone—Rash—Cyclosporine—psoriasis	0.000103	0.000754	CcSEcCtD
Abiraterone—Dermatitis—Cyclosporine—psoriasis	0.000103	0.000753	CcSEcCtD
Abiraterone—Anaemia—Methotrexate—psoriasis	0.000103	0.000748	CcSEcCtD
Abiraterone—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	0.000102	0.00432	CbGpPWpGaD
Abiraterone—Vomiting—Mycophenolate mofetil—psoriasis	0.000102	0.000742	CcSEcCtD
Abiraterone—Rash—Mycophenolate mofetil—psoriasis	0.000101	0.000735	CcSEcCtD
Abiraterone—Dermatitis—Mycophenolate mofetil—psoriasis	0.000101	0.000735	CcSEcCtD
Abiraterone—Diarrhoea—Hydrocortisone—psoriasis	9.97e-05	0.000727	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Prednisone—psoriasis	9.88e-05	0.00072	CcSEcCtD
Abiraterone—Asthenia—Triamcinolone—psoriasis	9.84e-05	0.000718	CcSEcCtD
Abiraterone—Body temperature increased—Betamethasone—psoriasis	9.84e-05	0.000718	CcSEcCtD
Abiraterone—Body temperature increased—Dexamethasone—psoriasis	9.84e-05	0.000718	CcSEcCtD
Abiraterone—Insomnia—Prednisone—psoriasis	9.8e-05	0.000715	CcSEcCtD
Abiraterone—Cough—Methotrexate—psoriasis	9.69e-05	0.000707	CcSEcCtD
Abiraterone—Dyspepsia—Prednisone—psoriasis	9.54e-05	0.000696	CcSEcCtD
Abiraterone—Chest pain—Methotrexate—psoriasis	9.45e-05	0.000689	CcSEcCtD
Abiraterone—Myalgia—Methotrexate—psoriasis	9.45e-05	0.000689	CcSEcCtD
Abiraterone—Rash—Prednisolone—psoriasis	9.41e-05	0.000686	CcSEcCtD
Abiraterone—Dermatitis—Prednisolone—psoriasis	9.4e-05	0.000685	CcSEcCtD
Abiraterone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	9.39e-05	0.000685	CcSEcCtD
Abiraterone—Fatigue—Prednisone—psoriasis	9.35e-05	0.000682	CcSEcCtD
Abiraterone—Discomfort—Methotrexate—psoriasis	9.34e-05	0.000681	CcSEcCtD
Abiraterone—Constipation—Prednisone—psoriasis	9.27e-05	0.000676	CcSEcCtD
Abiraterone—Vomiting—Hydrocortisone—psoriasis	9.26e-05	0.000676	CcSEcCtD
Abiraterone—Rash—Hydrocortisone—psoriasis	9.19e-05	0.00067	CcSEcCtD
Abiraterone—Dermatitis—Hydrocortisone—psoriasis	9.18e-05	0.000669	CcSEcCtD
Abiraterone—Infection—Methotrexate—psoriasis	9e-05	0.000656	CcSEcCtD
Abiraterone—ALB—Folate Metabolism—CAT—psoriasis	8.98e-05	0.0038	CbGpPWpGaD
Abiraterone—Asthenia—Dexamethasone—psoriasis	8.93e-05	0.000651	CcSEcCtD
Abiraterone—Asthenia—Betamethasone—psoriasis	8.93e-05	0.000651	CcSEcCtD
Abiraterone—Skin disorder—Methotrexate—psoriasis	8.8e-05	0.000642	CcSEcCtD
Abiraterone—ALB—Vitamin B12 Metabolism—CRP—psoriasis	8.77e-05	0.00371	CbGpPWpGaD
Abiraterone—Vomiting—Triamcinolone—psoriasis	8.72e-05	0.000636	CcSEcCtD
Abiraterone—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	8.72e-05	0.00369	CbGpPWpGaD
Abiraterone—Rash—Triamcinolone—psoriasis	8.65e-05	0.000631	CcSEcCtD
Abiraterone—Dermatitis—Triamcinolone—psoriasis	8.64e-05	0.00063	CcSEcCtD
Abiraterone—ALB—Vitamin B12 Metabolism—APOE—psoriasis	8.58e-05	0.00363	CbGpPWpGaD
Abiraterone—Body temperature increased—Prednisone—psoriasis	8.57e-05	0.000625	CcSEcCtD
Abiraterone—CYP17A1—Metabolism—NDUFA5—psoriasis	8.54e-05	0.00361	CbGpPWpGaD
Abiraterone—Diarrhoea—Betamethasone—psoriasis	8.52e-05	0.000621	CcSEcCtD
Abiraterone—Diarrhoea—Dexamethasone—psoriasis	8.52e-05	0.000621	CcSEcCtD
Abiraterone—Musculoskeletal discomfort—Methotrexate—psoriasis	8.25e-05	0.000602	CcSEcCtD
Abiraterone—ALB—Folate Metabolism—IL4—psoriasis	8.25e-05	0.00349	CbGpPWpGaD
Abiraterone—Insomnia—Methotrexate—psoriasis	8.19e-05	0.000598	CcSEcCtD
Abiraterone—Dyspnoea—Methotrexate—psoriasis	8.08e-05	0.000589	CcSEcCtD
Abiraterone—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	8.06e-05	0.00341	CbGpPWpGaD
Abiraterone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8e-05	0.00339	CbGpPWpGaD
Abiraterone—Dyspepsia—Methotrexate—psoriasis	7.97e-05	0.000582	CcSEcCtD
Abiraterone—CYP17A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	7.96e-05	0.00337	CbGpPWpGaD
Abiraterone—Vomiting—Dexamethasone—psoriasis	7.91e-05	0.000577	CcSEcCtD
Abiraterone—Vomiting—Betamethasone—psoriasis	7.91e-05	0.000577	CcSEcCtD
Abiraterone—Rash—Dexamethasone—psoriasis	7.85e-05	0.000572	CcSEcCtD
Abiraterone—Rash—Betamethasone—psoriasis	7.85e-05	0.000572	CcSEcCtD
Abiraterone—Dermatitis—Dexamethasone—psoriasis	7.84e-05	0.000572	CcSEcCtD
Abiraterone—Dermatitis—Betamethasone—psoriasis	7.84e-05	0.000572	CcSEcCtD
Abiraterone—Gastrointestinal disorder—Methotrexate—psoriasis	7.82e-05	0.00057	CcSEcCtD
Abiraterone—Fatigue—Methotrexate—psoriasis	7.81e-05	0.00057	CcSEcCtD
Abiraterone—Asthenia—Prednisone—psoriasis	7.78e-05	0.000567	CcSEcCtD
Abiraterone—CYP3A4—Biological oxidations—CYP2S1—psoriasis	7.5e-05	0.00317	CbGpPWpGaD
Abiraterone—Diarrhoea—Prednisone—psoriasis	7.42e-05	0.000541	CcSEcCtD
Abiraterone—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	7.4e-05	0.00313	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—CYP2S1—psoriasis	7.26e-05	0.00307	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.17e-05	0.00303	CbGpPWpGaD
Abiraterone—Body temperature increased—Methotrexate—psoriasis	7.16e-05	0.000522	CcSEcCtD
Abiraterone—ALB—Selenium Micronutrient Network—CAT—psoriasis	7.14e-05	0.00302	CbGpPWpGaD
Abiraterone—ALB—Folate Metabolism—CRP—psoriasis	7.13e-05	0.00302	CbGpPWpGaD
Abiraterone—Vomiting—Prednisone—psoriasis	6.89e-05	0.000503	CcSEcCtD
Abiraterone—Rash—Prednisone—psoriasis	6.83e-05	0.000499	CcSEcCtD
Abiraterone—Dermatitis—Prednisone—psoriasis	6.83e-05	0.000498	CcSEcCtD
Abiraterone—SULT2A1—Metabolism—CARM1—psoriasis	6.68e-05	0.00283	CbGpPWpGaD
Abiraterone—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	6.62e-05	0.0028	CbGpPWpGaD
Abiraterone—ALB—Folate Metabolism—ICAM1—psoriasis	6.56e-05	0.00277	CbGpPWpGaD
Abiraterone—Asthenia—Methotrexate—psoriasis	6.5e-05	0.000474	CcSEcCtD
Abiraterone—CYP3A4—Tryptophan metabolism—CAT—psoriasis	6.47e-05	0.00274	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.24e-05	0.00264	CbGpPWpGaD
Abiraterone—Diarrhoea—Methotrexate—psoriasis	6.2e-05	0.000452	CcSEcCtD
Abiraterone—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	6.13e-05	0.00259	CbGpPWpGaD
Abiraterone—Vomiting—Methotrexate—psoriasis	5.76e-05	0.00042	CcSEcCtD
Abiraterone—Rash—Methotrexate—psoriasis	5.71e-05	0.000417	CcSEcCtD
Abiraterone—Dermatitis—Methotrexate—psoriasis	5.71e-05	0.000416	CcSEcCtD
Abiraterone—ALB—Selenium Micronutrient Network—CRP—psoriasis	5.67e-05	0.0024	CbGpPWpGaD
Abiraterone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.58e-05	0.00236	CbGpPWpGaD
Abiraterone—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	5.21e-05	0.0022	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—NDUFA5—psoriasis	5.15e-05	0.00218	CbGpPWpGaD
Abiraterone—ALB—SLC-mediated transmembrane transport—CP—psoriasis	5.11e-05	0.00216	CbGpPWpGaD
Abiraterone—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	5.1e-05	0.00216	CbGpPWpGaD
Abiraterone—ALB—Folate Metabolism—IFNG—psoriasis	4.99e-05	0.00211	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.8e-05	0.00203	CbGpPWpGaD
Abiraterone—ABCC1—Transmembrane transport of small molecules—CP—psoriasis	4.79e-05	0.00202	CbGpPWpGaD
Abiraterone—ABCC1—Transmembrane transport of small molecules—CARM1—psoriasis	4.56e-05	0.00193	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—CYP2S1—psoriasis	4.38e-05	0.00185	CbGpPWpGaD
Abiraterone—ALB—Folate Metabolism—NFKB1—psoriasis	4.15e-05	0.00176	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—CAT—psoriasis	4.11e-05	0.00174	CbGpPWpGaD
Abiraterone—ALB—Vitamin B12 Metabolism—TNF—psoriasis	3.97e-05	0.00168	CbGpPWpGaD
Abiraterone—ALB—Selenium Micronutrient Network—IFNG—psoriasis	3.96e-05	0.00168	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.8e-05	0.00161	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—CARM1—psoriasis	3.54e-05	0.0015	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.31e-05	0.0014	CbGpPWpGaD
Abiraterone—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	3.3e-05	0.0014	CbGpPWpGaD
Abiraterone—ALB—Platelet degranulation—VEGFA—psoriasis	3.23e-05	0.00137	CbGpPWpGaD
Abiraterone—ALB—Folate Metabolism—TNF—psoriasis	3.23e-05	0.00137	CbGpPWpGaD
Abiraterone—ALB—Vitamin B12 Metabolism—IL6—psoriasis	3.2e-05	0.00135	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—APOE—psoriasis	3.19e-05	0.00135	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—ITGAL—psoriasis	3.11e-05	0.00131	CbGpPWpGaD
Abiraterone—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	3.08e-05	0.0013	CbGpPWpGaD
Abiraterone—ALB—Folate Metabolism—TP53—psoriasis	2.85e-05	0.0012	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—NDUFA5—psoriasis	2.81e-05	0.00119	CbGpPWpGaD
Abiraterone—ALB—Metabolism—NDUFA5—psoriasis	2.8e-05	0.00118	CbGpPWpGaD
Abiraterone—SULT2A1—Metabolism—PPARG—psoriasis	2.78e-05	0.00118	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.62e-05	0.00111	CbGpPWpGaD
Abiraterone—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.61e-05	0.0011	CbGpPWpGaD
Abiraterone—ALB—Folate Metabolism—IL6—psoriasis	2.61e-05	0.0011	CbGpPWpGaD
Abiraterone—ALB—Transmembrane transport of small molecules—CP—psoriasis	2.6e-05	0.0011	CbGpPWpGaD
Abiraterone—ALB—Selenium Micronutrient Network—TNF—psoriasis	2.57e-05	0.00109	CbGpPWpGaD
Abiraterone—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	2.48e-05	0.00105	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—CYP2S1—psoriasis	2.39e-05	0.00101	CbGpPWpGaD
Abiraterone—ALB—Metabolism—CYP2S1—psoriasis	2.38e-05	0.00101	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—NDUFA5—psoriasis	2.31e-05	0.000977	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.29e-05	0.000971	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—CAT—psoriasis	2.18e-05	0.000922	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—CARM1—psoriasis	2.14e-05	0.000905	CbGpPWpGaD
Abiraterone—ALB—Selenium Micronutrient Network—IL6—psoriasis	2.07e-05	0.000876	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2e-05	0.000845	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—CYP2S1—psoriasis	1.96e-05	0.00083	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—APOE—psoriasis	1.69e-05	0.000717	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—NDUFA5—psoriasis	1.51e-05	0.000638	CbGpPWpGaD
Abiraterone—CYP17A1—Metabolism—PPARG—psoriasis	1.48e-05	0.000624	CbGpPWpGaD
Abiraterone—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.43e-05	0.000606	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—CAT—psoriasis	1.32e-05	0.000556	CbGpPWpGaD
Abiraterone—ABCC1—Disease—HLA-A—psoriasis	1.31e-05	0.000553	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—CYP2S1—psoriasis	1.28e-05	0.000543	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—NOS2—psoriasis	1.28e-05	0.000539	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.25e-05	0.00053	CbGpPWpGaD
Abiraterone—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.25e-05	0.000527	CbGpPWpGaD
Abiraterone—ABCC1—Disease—APOE—psoriasis	1.22e-05	0.000516	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—CARM1—psoriasis	1.17e-05	0.000494	CbGpPWpGaD
Abiraterone—ALB—Metabolism—CARM1—psoriasis	1.16e-05	0.000491	CbGpPWpGaD
Abiraterone—ABCC1—Disease—NOS2—psoriasis	1.14e-05	0.000481	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.09e-05	0.000462	CbGpPWpGaD
Abiraterone—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.09e-05	0.000459	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—APOE—psoriasis	1.02e-05	0.000432	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—CARM1—psoriasis	9.59e-06	0.000406	CbGpPWpGaD
Abiraterone—ABCC1—Disease—TYK2—psoriasis	9.31e-06	0.000394	CbGpPWpGaD
Abiraterone—ABCC1—Metabolism—PPARG—psoriasis	8.9e-06	0.000377	CbGpPWpGaD
Abiraterone—ABCC1—Disease—CD4—psoriasis	8.42e-06	0.000356	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—VEGFA—psoriasis	7.39e-06	0.000312	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—CAT—psoriasis	7.18e-06	0.000304	CbGpPWpGaD
Abiraterone—ALB—Metabolism—CAT—psoriasis	7.14e-06	0.000302	CbGpPWpGaD
Abiraterone—ABCC1—Disease—STAT3—psoriasis	6.52e-06	0.000276	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—CARM1—psoriasis	6.27e-06	0.000265	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—CAT—psoriasis	5.9e-06	0.000249	CbGpPWpGaD
Abiraterone—ALB—Hemostasis—TP53—psoriasis	5.58e-06	0.000236	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—APOE—psoriasis	5.58e-06	0.000236	CbGpPWpGaD
Abiraterone—ALB—Metabolism—APOE—psoriasis	5.55e-06	0.000235	CbGpPWpGaD
Abiraterone—CYP2C8—Metabolism—PPARG—psoriasis	4.86e-06	0.000206	CbGpPWpGaD
Abiraterone—ALB—Metabolism—PPARG—psoriasis	4.83e-06	0.000204	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—APOE—psoriasis	4.58e-06	0.000194	CbGpPWpGaD
Abiraterone—ABCC1—Disease—IL6—psoriasis	4.55e-06	0.000193	CbGpPWpGaD
Abiraterone—CYP2D6—Metabolism—PPARG—psoriasis	3.99e-06	0.000169	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—CAT—psoriasis	3.85e-06	0.000163	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—APOE—psoriasis	3e-06	0.000127	CbGpPWpGaD
Abiraterone—CYP3A4—Metabolism—PPARG—psoriasis	2.61e-06	0.00011	CbGpPWpGaD
